Apellis Pharmaceuticals (APLS) Receivables - Other (2022 - 2025)
Apellis Pharmaceuticals (APLS) has 4 years of Receivables - Other data on record, last reported at $496000.0 in Q4 2025.
- For Q4 2025, Receivables - Other fell 89.04% year-over-year to $496000.0; the TTM value through Dec 2025 reached $496000.0, down 89.04%, while the annual FY2025 figure was $496000.0, 89.04% down from the prior year.
- Receivables - Other reached $496000.0 in Q4 2025 per APLS's latest filing, down from $6.5 million in the prior quarter.
- Across five years, Receivables - Other topped out at $6.5 million in Q3 2025 and bottomed at $496000.0 in Q4 2025.
- Average Receivables - Other over 4 years is $3.7 million, with a median of $4.4 million recorded in 2024.
- Peak YoY movement for Receivables - Other: soared 181.72% in 2024, then crashed 89.04% in 2025.
- A 4-year view of Receivables - Other shows it stood at $1.4 million in 2022, then skyrocketed by 111.79% to $3.1 million in 2023, then skyrocketed by 48.17% to $4.5 million in 2024, then plummeted by 89.04% to $496000.0 in 2025.
- Per Business Quant database, its latest 3 readings for Receivables - Other were $496000.0 in Q4 2025, $6.5 million in Q3 2025, and $5.9 million in Q2 2025.